Skip to Content
Merck

[Clinical strategies for prevention of drug-induced urinary calculi].

Clinical calcium (2011-10-01)
Yasuo Kohjimoto, Yumiko Sasaki, Isao Hara
ABSTRACT

Drug-induced urinary calculi, although they account for only 1-2% of urinary calculi, deserve consideration because most of them are preventable. In the drug-containing calculi resulting from the crystallization of a certain drug and its metabolites in the urine, stone analysis can identify the responsible drug. While, in the drug-induced metabolic calculi caused by interference with calcium, oxalate and purine metabolism, careful clinical inquiry is necessary to reveal involvement of a certain drug in stone formation. Better awareness of the possible drugs with lithogenic potential and close surveillance of patients on long-term treatment with these drugs are necessary. Especially, in patients with a history of urolithiaisis, prescription of lithogenic drugs deserve careful consideration.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Triamterene, ≥99%
Supelco
Benzbromarone, analytical standard
Benzbromarone, European Pharmacopoeia (EP) Reference Standard
Supelco
Florisil®, 100-200 mesh, fine powder